Reduces elevated intraocular pressure (IOP). ANDA 220398, held by Mankind Pharma. Brimonidine Tartrate.
As of Nov 16, 2026, ANDA 220398 (Brimonidine Tartrate), held by Mankind Pharma, was first approved by FDA on Apr 16, 2026, with 0 approved supplements and 0 published complete response letters.
Brimonidine tartrate ophthalmic solution 0.1% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Brimonidine Tartrate0.1% · solution/drops;ophthalmic | Brimonidine Tartrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters